Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tia Chase

Physician Assistant Huron, SD Physician Assistant

NPI 1861904476 CMS profile 10556248

111 4Th St Se, Huron, SD 57350

Open in the dashboard

General payments

$3,522

248 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tia Chase of Huron, SD is reported in the CMS Open Payments database as having received $3,522 across 248 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $211 13
2024 General $1,030 57
2023 General $809 59
2022 General $628 46
2021 General $845 73

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tia Chase
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Tia Chase were reported at $211. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Tia Chase Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $845 $132 $37–$438 $132
2022 $628 $155 $48–$522 $149
2023 $809 $167 $52–$557 $160
2024 $1,030 $178 $55–$600 $164
2025 $211 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $569 46 payments
  2. Lilly USA, LLC $427 30 payments
  3. Pfizer Inc. $385 34 payments
  4. Janssen Pharmaceuticals, Inc $306 26 payments
  5. AbbVie, Inc. $290 18 payments
  6. Grifols USA, LLC $209 10 payments
  7. AstraZeneca Pharmaceuticals LP $162 4 payments
  8. Amarin Pharma Inc. $155 13 payments
  9. Astellas Pharma US Inc $141 9 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $117 8 payments
  11. Other $760 50 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,522 248 payments
Products named General payments · program years 2021–2025
  1. Ozempic $443 37 payments
  2. RYBELSUS $423 36 payments
  3. XARELTO $306 26 payments
  4. MOUNJARO $293 19 payments
  5. Prolastin-C Liquid $209 10 payments
  6. UBRELVY $179 11 payments
  7. FARXIGA $162 4 payments
  8. COMIRNATY $158 13 payments
  9. Vascepa $155 13 payments
  10. JARDIANCE $134 11 payments
  11. Other $2,907 199 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 83 drugs

Part D claims

2,310

Median for Physician Assistant: 241

Drug cost

$104,032

Median for Physician Assistant: $4,110

Branded share of claims

19.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 24 $15,171
Januvia Sitagliptin Phosphate Brand 17 $13,829
Ozempic Semaglutide Brand 13 $12,052
Myrbetriq Mirabegron Brand 25 $10,575
Restasis Cyclosporine Brand 12 $8,223
Praluent Pen Alirocumab Brand 12 $5,537
Vascepa Icosapent Ethyl Brand 12 $4,885
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 13 $4,525
Paxlovid Nirmatrelvir/Ritonavir Brand 11 $2,858
Novolin R Insulin Regular, Human Brand 12 $1,996

The 10 drugs with the highest cost, of 83 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 91 billing codes

Paid by Medicare

$41,719

Of which drugs: $8,587

Medicare patients

124

Average age 69

Services billed

1,792

64 women, 60 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Arthritis 24%
Depression 23%
Diabetes 20%
Chronic kidney disease 19%
Ischemic heart disease 14%
Atrial fibrillation 10%
Cancer 10%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 15 15 $329

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $61
  • Boehringer Ingelheim Pharmaceuticals, Inc. $44
$105 — —
MOUNJARO
  • Lilly USA, LLC $89
$89 — —
Prolastin-C Liquid
  • Grifols USA, LLC $67
$67 — —
Veozah
  • Astellas Pharma US Inc $62
$62 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $60
$60 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

248 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record